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Abstract: Angiogenesis is involved in the inflammation and proliferation stages of wound healing,
to bring inflammatory cells to the wound and provide a microvascular network to maintain new tissue
formation. An excess of inflammation, however, leads to prolonged wound healing and scar formation,
often resulting in unfavourable outcomes such as amputation. CC-chemokines play key roles in
the promotion of inflammation and inflammatory-driven angiogenesis. Therefore, inhibition of the
CC-chemokine class may improve wound healing. We aimed to determine if the broad-spectrum
CC-chemokine inhibitor “35K” could accelerate wound healing in vivo in mice. In a murine wound
healing model, 35K protein or phosphate buffered saline (PBS, control) were added topically daily
to wounds. Cohorts of mice were assessed in the early stages (four days post-wounding) and
in the later stages of wound repair (10 and 21 days post-wounding). Topical application of the
35K protein inhibited CC-chemokine expression (CCL5, CCL2) in wounds and caused enhanced
blood flow recovery and wound closure in early-mid stage wounds. In addition, 35K promoted
neovascularisation in the early stages of wound repair. Furthermore, 35K treated wounds had
significantly lower expression of the p65 subunit of NF-κB, a key inflammatory transcription factor,
and augmented wound expression of the pro-angiogenic and pro-repair cytokine TGF-β. These
findings show that broad-spectrum CC-chemokine inhibition may be beneficial for the promotion of
wound healing.
Keywords: chemokine; angiogenesis; wound; healing; inflammation
1. Introduction
Wound healing is a complex multistep process comprised of three overlapping but distinct phases:
inflammation, proliferation and remodelling. It begins with the inflammation phase, where neutrophils
and macrophages are recruited to the wound site to remove cell debris and phagocytose infectious
pathogens. This is followed by the proliferation stage, where re-epithelialization and the formation
of granulation tissue begin to close the wound. Angiogenesis, the formation of new blood vessels,
is important during both the inflammation and proliferation phases, forming angiogenic capillary
sprouts that allow for recruitment of inflammatory cells to the wound for debris removal, invasion of
the fibrin/fibronectin-rich wound clot, and reorganization of a microvascular network to maintain the
new granulation tissue being formed [1]. Finally, during the remodelling phase, fibroblasts reorganize
the collagen matrix, forming a closed wound [2]. All three phases must occur in the proper sequence
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and time frame in order for a wound to heal successfully. Excessive macrophage accumulation during
the inflammation and proliferation stages may prolong the inflammatory response leading to delayed
wound healing and scar formation at the injury site. Macrophage phenotype has also been reported
to change throughout the wound healing process, alternating between inflammatory M1 and repair
M2 phenotypes [3]. The regulation of these phenotypes has been shown to affect wound functionality
and the extent of scar tissue [4]. Wounds that exhibit impaired healing frequently enter a state of
pathological inflammation, with most chronic wounds developing into ulcers. The incidence of chronic
wounds is associated with ischemia, diabetes mellitus, venous stasis disease or pressure [5]. Chronic,
non-healing wounds greatly impact a person’s quality of life and, when left untreated, sometimes lead
to amputation, resulting in an enormous health care burden [6,7]. While current therapies provide some
relief, there is a need for the continued development of novel therapies that address the debilitating
effects of impaired wound healing.
CC-chemokines are small inflammatory cytokines that have been shown to play a key role in the
induction of inflammation and inflammation-mediated angiogenesis. In the wound healing process,
macrophage infiltration is highly regulated by CC-chemokine gradients released by hyper-proliferating
keratinocytes, fibroblasts and other macrophages [8,9]. In human wounds, a host of CC-chemokines
including CCL1, CCL2, CCL3, CCL4, CCL5 and CCL7 are expressed during the first week after injury
and high levels of CCL2 have been found in human burns [10,11]. Additionally, studies in excisional
wounds have found localized expression of CCL2 and CCL3 in the epidermis, while CCL3 is expressed
in follicular epithelium and sebaceous glands [12]. CC-chemokines regulate key angiogenic processes
such as the recruitment of inflammatory cells to the wound, to provide support for proliferating and
migrating cells [13], and the formation of granulation tissue [9]. Furthermore, incubation with the
recombinant CC-chemokines CCL2 and CCL5 stimulate angiogenic functions such as endothelial
cell tubulogenesis and migration [14–18]. Therefore, manipulation of the CC-chemokine family
may modulate key wound healing processes to confer benefits. To date, studies have inhibited a
single CC-chemokine and shown modest or no effect on wound healing. CCL2 knockout mice have
delayed re-epithelialization and reduced angiogenesis in the early stages of wound repair, whilst
the CCL3 knockout mice have normal wound healing [19]. Similarly, CCR1 knockout models have
no alteration in wound healing [20]. Inhibition of a single CC-chemokine, however, may not be
as effective in modulating wound healing due to redundancies in CC-chemokine signalling [21,22].
A broad-spectrum CC-chemokine inhibition approach may therefore have increased efficacy.
The broad-spectrum CC-chemokine inhibitor “35K” is a 35 kDa soluble protein produced by
the Vaccinia virus that uniquely inhibits only the CC-chemokine class [23]. It recognizes and binds
to common structural features shared by most CC-chemokines, preventing binding to their cognate
receptors [24]. Broad-spectrum CC-chemokine inhibition using 35K inhibits a host of inflammatory
diseases including atherosclerosis, acute peritonitis, hepatitis and liver fibrosis [25–28]. Given the
inhibitory effects of 35K on inflammatory-mediated diseases and the role of CC-chemokines in
angiogenesis, we sought to elucidate the effect of broad-spectrum CC-chemokine inhibition on wound
healing. We found that topical application of 35K enhanced wound closure, blood flow perfusion and
neovascularisation at the early-mid stages of wound healing. Augmentation of wound angiogenesis
by 35K was mediated via an increase in the pro-angiogenic and pro-repair cytokine TGF-β. In addition,
35K treatment inhibited wound levels of inflammatory transcription factor NF-κB and reduced collagen
deposition at the late stages of wound healing in the 35K-treated wounds, suggesting a reduction in
scar formation. Taken together, these findings show that broad-spectrum inhibition of CC-chemokines
may be beneficial for the promotion of wound healing by suppressing inflammation and promoting
wound closure and neovascularisation and reducing scar formation.
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2. Results
2.1. Topical 35K Increases Wound Blood Perfusion and the Rate of Wound Closure in Early-Mid Stage
Wound Repair
Topical treatment of wounds with 35K protein caused significantly faster wound closure
throughout the early to mid-stages of wound healing at Day 7 (42%, p < 0.05) and Day 8 (33%, p < 0.05)
compared to PBS treated wounds (Figure 1a). Using Laser Doppler imaging, it was revealed that 35K
protein augmented wound blood perfusion (Figure 1b). The Laser Doppler Index (LDI), used as a
marker of wound angiogenesis and determined as the ratio of 35K:PBS wounds, was significantly
elevated in the 35K treated wounds in the early stages following wounding (Day 3, 4), compared to
PBS control wounds (values above 100% indicate increased wound blood perfusion with 35K treatment
relative to PBS control). In the later stages of the wound healing process, at seven days post-wounding,
blood perfusion started to decline in wounds treated with 35K, compared to the PBS treated control
wounds. After Day 7, blood perfusion fluctuated along the baseline and very little blood perfusion
was detected. There were no significant increases or decreases to the end point.
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Figure 1. Topical 35K increases the rate of wound closure and wound blood perfusion in early-mid 
stage wound repair. Two full thickness wounds were created on C57Bl/6J mice (n = 7–12). Mice 
received daily topical application of 35K protein (200 nM) or PBS (vehicle). (a) representative images 
of the wounds and wound blood perfusion using Laser Doppler imaging (high (red) to low (blue) 
blood flow); (b) wound area was calculated from the average of three daily diameter measurements 
along the x-, y- and z-axes. Wound closure is expressed as a percentage of initial wound area at Day 
0. Black circles are PBS treated wounds; grey triangles are 35K treated wounds; and (c) the 35K:PBS 
wound blood flow perfusion ratio was determined using Laser Doppler imaging (LDI). Data is 
represented as mean ± SEM. Points above the dotted line represent an improvement with 35K 
treatment. Statistical analysis was performed by an unpaired two-tailed t-test. * p < 0.05 compared to 
PBS treated wounds. 
Figure 1. Topical 35K increases the rate of wound closure and wound blood perfusion in early-mid
stage wound repair. Two full thickness wounds were created on C57Bl/6J mice (n = 7–12). Mice received
daily topical application of 35K protein (200 nM) or PBS (vehicle). (a) representative images of the
wounds and wound blood perfusion using Laser Doppler imaging (high (red) to low (blue) blood flow);
(b) wound area was calculated from the average of three daily diameter measurements along the x-, y-
and z-axes. Wound closure is expressed as a percentag of initial wound area at Day 0. Black circles
are PBS treated wounds; grey triangles are 35K treated wounds; and (c) the 35K:PBS wound blood
flow perfusi n ratio was determined using Laser Doppler im ging (LDI). Dat is represented s
mean ± SEM. Points above the dotted line repres nt an improvement with 35K treatment. Statistical
analysis was performed by an unpair d two-tailed t-test. * p < 0.05 compared to PBS treated wounds.
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2.2. Inhibition of CC-Chemokines by 35K Increases Neovessel Formation in Early Stage Wounds but Decreases
Neovessels in Late Stage Wounds
To investigate wound angiogenesis, neovessels and arterioles were assessed. In the early stages
of wound healing (Day 4), there was an increase in the presence of wound neovessels in the 35K
treated wounds as determined by CD31+ staining (182%, p < 0.05, Figure 2a). However, at Day 10
post-wounding, there were significantly fewer wound neovessels (39% decrease, p < 0.05) following
35K treatment. At Day 21, there were no differences in neovessels between 35K and PBS treated
wounds. A similar biphasic pattern was also seen with the arterioles (α-actin+ staining), although,
at Day 4, the trend for an increase in arterioles did not reach significance, but there was a significant
48% decrease in arterioles (p < 0.05) in the 35K treated wounds at Day 10 post-wounding (Figure 2b).
No CD31+ and α-actin+ staining is detected in IgG controls (Figure S1).
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neovessels (stained brown, noted by black arrows) and (b) α-SMC+ arterioles (stained pink, noted by 
black arrows). Three tiled images were taken per wound (n = 7–12/treatment). Scale bars represent 50 
μm. Data is represented as mean ± SEM. Statistical analysis was performed by an unpaired two-tailed 
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expression was significantly higher in 35K-treated wounds in the early stages of wound repair (Day 
4 post-wounding, 88%, p < 0.05, Figure 3a). However, in the later stages post-wounding (Day 10), the 
expression of TGF-β had normalised back to control levels. There were no differences in VEGF 
protein levels at Day 4 post-wounding between treatment groups. In the later stages, wounds from 
both treatment groups had significantly lower levels of VEGF protein, compared to wounds at Day 
10 (p < 0.01). The protein levels of fibroblast growth factor-2 (FGF-2), were also measured, but no 
Figure 2. Inhibition of CC-chemokines by 35K increases neovessel formation in the early stages
of wound repair but decreases neovessels in later stages. Immunocytochemistry was used to
detect the presence of neovessels and arterioles. Photomicrographs represent wounds stained for
(a) CD31+ neovessels (stained brown, noted by black arrows) and (b) α-SMC+ arterioles (stained pink,
noted by black arrows). Three tiled images were taken per wound (n = 7–12/treatment). Scale bars
represent 50 µm. Data is represented as mean± SEM. Statistical analysis was performed by an unpaired
two-tailed t-test. * p < 0.05 compared to PBS treated wounds.
2.3. Inhibition of CC-Chemokines by 35K Modulates Pro-Angiogenic Markers TGF-β and Vascular Endothelial
Growth Facto (VEGF) in Early and Late St ge Wounds
T e ression of key angiogenic marke s TGF-β and vascul r endothelial growth factor (VEGF),
known to be involved in w un healing, were measured n xt. Inte stingly, TGF-β expression was
significantly higher n 35K-treated wounds in th early stages of wound repair (Day 4 post-wounding,
88%, p < 0.05, Figure 3a). However, in the later stages post-wounding (Day 10), the expression of
TGF-β had normalised back to control levels. There were no differenc s i VEGF prot in levels at
Day 4 post-wounding between treatmen groups. In the later stages, wounds from both treatment
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groups had significantly lower levels of VEGF protein, compared to wounds at Day 10 (p < 0.01).
The protein levels of fibroblast growth factor-2 (FGF-2), were also measured, but no differences were
detected (Figure S2a). Neither were there changes in wound protein levels of HIF-1α, a regulator of
VEGF (Figure S2b).
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2.5. Inhibition of CC-Chemokines by 35K Decreases Collagen Formation in Late Stage Wounds
Milligan’s trichrome staining was used to detect the collagen content in the wounds as a marker
of tissue remodelling. hile no differences in collagen deposition were observed at Day 4 and 21
between 35K and PBS wounds, a 25% decrease (p < 0.05) in collagen content was seen in the 35K
treated wounds at Day 10 (Figure 5a). The picrosirius red stain was imaged under polarized light to
differentiate between type III and type I collagen. There was 10–100 times more type I collagen to type
III collagen (across Day 4–21), but there were no significant differences between 35K and PBS treated
wounds at each time point (Figure 5b).
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Figure 5. Inhibition of CC-che okines by 35K decreases collagen formation in Day 10 wounds.
Masson’s trichrome staining was used to detect the collagen content in the wounds. (a) green staining
in wound sections is collagen, purple staining are nuclei; (b) to differentiate collagen type, wound
sections were stained red with picrosirius and imaged under polarized light. Green represents Type III
collagen, yellow t red represents Type I collagen. Three tiled images wer taken per wound (n = 12 or
7/treatment). Scale bars represent 50 µm. Data is represented as mean ± SEM. tatistic l analysis was
performed by an unpaired two-tailed t-test. * p < 0.05 compared to PBS treated wounds.
2.6. Topical 35K Suppresses CC-Chemokine Expression in the Wounds
The effect of 35K on wound CC-chemokine protein and gene expression was measured. There
was a significant decrease in CCL5 protein levels in 35K treated wounds at both the Day 4 (36%,
p < 0.05) and Day 10 (66%, p < 0.05) time points (Figure 6a). There were also similar decreases in CCL5
mRNA levels in wounds treated with 35K (Day 4: 32%, ns and Day 10: 62%, p < 0.05, Figure 6b). CCL2
protein levels were lower in wounds at the Day 4 time point (41%, p < 0.05, Figure 6c), but the trend
for a decline at the Day 10 time point did not reach significance following 35K treatment. This was
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consistent for wound CCL2 mRNA levels in which 35K treatment decreased CCL2 wound mRNA at
the Day 4 time point (36%, p < 0.05, Figure 6d), with no significant decrease in Day 10 wounds.Int. J. Mol. Sci. 2017, 18, 155 8 of 14 
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ound healing often leading to severe unfavourable outcomes such as amputation. This highlights the
need to develop novel agents that promote wound recovery. CC-chemokines have been shown to play
a key role in the promotion of inflammation and inflammatory-induced angiogenesis, two important
processes involved in wound healing. To date, only single CC-chemokine intervention studies have
been done, with minimal to no benefit, suggesting that a broad-spectrum inhibition approach may
have improved efficacy. In this study, we report that topical application of the broad-spectrum
CC-che okine inhibitor “35K” decreased wound CCL5 and CCL2 protein levels, leading to enhanced
wound healing and wound neovascularisation during the early stages of wound healing. Histological
analysis of wounds showed that 35K treatment significantly increased neovessels in the early stages of
wound healing, when angiogenesis is most important. Mechanistically, we found that the classical
VEGF-mediated angiogenic pathway was not responsible for the augmentation of angiogenesis by
35K, but, instead, 35K elevated the pro-angiogenic and pro-repair cytokine TGF-β. Furthermore,
35K treated wounds had significantly lower mRNA levels of p65, the active subunit of the inflammatory
transcription factor NF-κB. In addition, 35K treated wounds at Day 10 had lower collagen content,
suggesting a reduction in scar formation. Taken together, these findings suggest that broad-spectrum
inhibition of CC-chemokines may be an alternate therapeutic approach to improve wound healing by
simultaneously suppressing inflam ation while augmenting neovascularisation at the critical early
stages of wound repair.
acroscopic wound measurements revealed that wound closure was faster in 35K treated wounds
compared to PBS treated control wounds. This was supported by the increased blood flow perfusion
observed during the early stages post-wounding in 35K treated wounds. At this stage (~Day 3),
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perfusion is critical to support the wound healing process to supply the wound with nutrients and
growth factors, and accelerate debris removal [2,29]. Increased blood flow perfusion also allows for
increased oxygenation to help maintain the newly forming wound tissue [30]. This early boost in
perfusion may support the increased closure seen at Day 7 and 8. By Day 7, wound blood perfusion
then started to decline in the 35K treated wounds. At this stage, remodelling is commencing, and, whilst
neovessels are still present, the impetus for new wound neovessels has started to decline, supporting
the decrease in wound blood perfusion at this stage. After Day 7 post-wounding, there is very little
detectable blood perfusion using the Laser Doppler for both treatments. Consistent with our blood
perfusion measurements, the current study also found that topical application of 35K increased the
presence of wound neovessels at Day 4, and, at Day 10, neovessels and arterioles were reduced in the
35K treated wounds. At this late stage, the wound has nearly healed, re-epithelialization is complete,
inflammation has ceased, a scar has formed and collagen remodelling from type III to type I collagen
begins [31]. Importantly, as the wound healing process is near-completion, angiogenesis may decline
to allow for continued remodelling [9,32]. The lower number of neovessels and arterioles seen at
Day 10 suggest that these wounds have healed quicker and have now entered the remodelling phase.
However, at Day 21, the wounds are further in the remodelling phase, bringing stability to neovessel
content. The reduction in collagen content of the 35K treated wounds at Day 10 may further lead to
reduced scar formation, as scars are mainly comprised of collagen [33]. At Day 21, the collagen content
returns to a stable level, when compared to PBS wounds. This suggests that whilst the wounds may
have less scar the stability of the skin is not compromised. Interestingly, at Day 4 there is 10 times more
type I collagen than type III, and, when the wound is completely healed and undergoing remodelling,
there is an increase of 50 times in type I collagen in wounds. These findings are consistent with
previous studies where reduced fibrosis was detected in the kidneys and lungs of mice following
inhibition of the chemokine receptors CCR1 or CCR5 [34–36].
Angiogenic mediators such as VEGF and FGF-2 are released by various cell types including
endothelial cells, fibroblasts, keratinocytes and macrophages. VEGF is primarily produced by
endothelial cells, whilst FGF-2 is produced by fibroblasts. Interestingly, 35K had no effect on these key
angiogenic mediators involved in wound healing. Furthermore, we found no change in wound HIF-1α
expression, which regulates VEGF and is triggered in response to tissue ischemia. This suggests
that there was sufficient blood perfusion and oxygenation to the wounds. VEGF is involved in
angiogenesis and synthesis of collagen in the wound [8,37]. It is produced by wound fibroblasts,
keratinocytes and macrophages [8,32,38]. VEGF levels remained unchanged in 35K treated wounds,
suggesting that VEGF is not involved in the augmentation of wound healing and wound angiogenesis
by 35K. An alternative suggestion is that VEGF expression increased very early post-wounding
with 35K, which was missed at the Day 4 time point. Studies have shown increases in VEGF just
24 h post-wounding [39], which then return to baseline once angiogenesis is underway. There was,
however, an increase in wound neovessels with 35K treatment at the Day 4 time point, despite
no changes in VEGF or HIF-1α. Interestingly, both VEGF and HIF-1α are induced by NF-κB in
inflammatory pathological angiogenesis. This study found that 35K significantly inhibited p65
(active NF-κB subunit) mRNA levels. This reduction in NF-κB may be part of the reason for the
lack of change in VEGF and HIF-1α and suggests that 35K was preventing pathological excessive
wound angiogenesis. Furthermore, the reduction in wound CC-chemokine levels by 35K would
also contribute to the suppression of pathological angiogenesis that can compromise wound repair
if it persists in the later stages of healing. The increase in angiogenesis seen during early wound
healing, where it is critical, is likely to be the result of increased TGF-β expression in the Day 4 35K
treated wounds. TGF-β increases key angiogenic functions including endothelial cell proliferation
and migration [40,41] TGF-β also has a number of roles in the wound repair process including
fibroblast proliferation, collagen formation and remodelling of the extracellular matrix [42] and the
initiation in the formation of granulation tissue [43]. TGF-β stimulates contraction of fibroblasts [44]
and promotes the migration of keratinocytes in the wound [45] which promotes wound closure. Taken
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together, our results demonstrate that 35K does not augment wound angiogenesis via the classical
HIF-1α/VEGF angiogenic pathway but rather through the induction of TGF-β, and may in fact
suppress excessive pathological angiogenesis in the mid-late stages of wound repair via inhibition of
NF-κB and CC-chemokine levels.
Despite the reduction in NF-κB by 35K, there were no changes in the number of wound
macrophages as may have been expected. Macrophages can be roughly divided into pro- and
anti-inflammatory phenotypes (M1 and M2) and both are involved in different stages of wound
healing [46]. Our results indicate an increase in the M2 macrophage phenotype during the early
wound healing stage (TGF-β, CD206), which is known to be associated with improved wound repair,
sufficient formation of granulation tissue and new vascular networks [46]. Interestingly, there was a
surprising increase in M1 macrophage markers at Day 10 (CD80, CD86), which is inconsistent with the
reduction in NF-κB at this time point. However, previous studies have shown that the presence of M1
macrophages at this late-stage does not affect the wound healing process [4].
There was a decrease in CCL5 and CCL2 protein in the tissues of wounds treated with the
CC-chemokine inhibitor 35K. This would typically be associated with a decrease in macrophages;
however, no significant reductions in macrophages were observed. A previous study reported
that despite dominant expression of CCL2 in dermal mouse wounds, a relatively low CCL2 level
correlated with optimal monocyte accumulation [12], indicating that a reduction, but not complete
ablation of CCL2, may not affect macrophage recruitment in the early stages of wound healing.
However, at the later stage (i.e., Day 10), the wound is preparing to enter the remodelling phase
in which macrophages undergo apoptosis and chemokines and angiogenesis are subsequently
reduced. Additionally, chemokines from other classes and other cytokines that are not affected by
35K (for example CX3CL1, IL-1, IFN-γ) are released from the wound site and may have assisted in
maintaining macrophage infiltration [47], even with lower CCL2 and CCL5 levels. This may explain
the consistent macrophage levels seen in our study despite the reduction in CC-chemokine levels.
4. Materials and Methods
4.1. Generation and Isolation of 35K Protein
A recombinant adenovirus overexpressing 35K (Ad35K) was generated as described previously [48].
To isolate 35K protein, 20 large flasks of Ad293 cells (293AD cell line, AD-100, Cell Biolabs Inc., San Diego,
CA USA) were infected with 5 × 1011 Ad35K virus particles. After 24–48 h, cells were microscopically
examined for evidence of complete cytopathic effect (CPE). 35K protein was isolated from Ad35K
viral media using anti-HA tagged agarose-conjugated beads (A2095, Sigma-Aldrich, St. Louis, MO,
USA). The media was run through a column packed with anti-HA agarose beads to bind 35K protein,
which was then eluted from the column with 3 M sodium thiocyanate into 1 M Trizma Base (pH 8).
Isolated 35K protein was dialyzed into sterile PBS and then filtered through 0.45 µm low protein binding
syringe filter (Pall Corporation, Port Washington, NY, USA). The concentration of 35K protein was
determined by measuring absorbance at 280 nm and aliquoted to 200 nM before freezing at −80 ◦C.
4.2. Murine Wound Healing Model
All experimental procedures and protocols were conducted with approval from the Sydney Local
Health District Animal Welfare Committee (#2013/027A), and conformed to the Guide for the Care
and Use of Laboratory Animals (United States National Institute of Health, Bethesda, MD, USA).
To explore the effect of broad-spectrum CC-chemokine inhibition on wound healing, a murine model
that closely mimics the human wound healing process was used [49]. Briefly, C57Bl6/J wildtype
mice were anesthetized by inhalation of methoxyflurane. Then, a 6 mm biopsy punch was used to
outline two circular full-thickness excisions, 5 mm in diameter, that include the panniculus carnosus
created on the dorsum, one on each side of the midline of the mouse. A 0.5 mm thick silicone
splint (Life Technologies, Carlsbad, CA, USA) was then placed around the wound and secured with
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interrupted sutures. For each mouse, one wound received purified 35K protein (200 nM in 50 µL PBS)
and the other endotoxin-free PBS (50 µL, vehicle control), topically applied daily beginning on the
day of wounding (Day 0). A transparent occlusive dressing (Opsite™ Flexifix™, Smith & Nephew,
London, UK) was then applied. Mice were given carprofen (5 mg/kg) daily 3 days post-surgery to
alleviate any pain. Digital images were taken and micro-callipers were used to measure wound area
daily along the x-, y- and z-axes. Blood perfusion in wound areas was determined using Laser Doppler
Perfusion Imaging (moorLDI2-IR, Moor Instruments, Devon, UK). For this study, two cohorts were
taken at 4 (n = 12), 10 (n = 12), or 21 (n = 7) days after wounding. Both PBS and 35K treated wounds
were collected for histological, protein and gene analysis.
4.3. Immunohistochemistry
Wound tissues were fixed in 4% (v/v) paraformaldehyde overnight, and then embedded in
paraffin. Furthermore, 5 µm wound sections were taken from the midpoint. Wounds were assessed for
neovessels by detection with rabbit polyclonal anti-CD31 antibody (1:100, ab28364, Abcam, Cambridge,
UK), arterioles by detection with mouse monoclonal smooth muscle α-actin antibody (1:100, A5691,
Sigma-Aldrich) and for macrophages by detection with mouse monoclonal anti-CD68 antibody
(1:100, ab31630, Abcam) staining. Secondary antibodies were pre-diluted horseradish peroxidase
(HRP) secondary antibody α-rabbit (K4011, Dako) or pre-diluted HRP secondary antibody α-mouse
(K4007, Dako, Glostrup, Denmark) for CD31 and CD68, respectively. The staining was visualized using
3,3′-Diaminobenzidine (DAB) (Dako) for CD31 and CD68 or Vector Red alkaline phosphatase substrate
(SK-5100, Vector Laboratories, Burlingame, CA, USA) for smooth muscle α-actin. Appropriate IgG
controls were used for all antibodies. Collagen was measured following Milligan’s trichrome staining.
Picrosirius red staining, imaged under polarized light, was used to differentiate type I and type
III collagen. For all histological quantification, three sections were imaged at 10× magnification,
the images were tiled and “stitched” to obtain the entire wound cross section for each treatment
group per mouse (n = 7–12) and assessed using Image-Pro® Premier 9.0 software (Media Cybernetics,
Rockville, MD, USA).
4.4. Protein Expression
Wound tissues were homogenized in lysis buffer (80 mM Tris HCl, 10 mM NaCl, 50 mM NaF,
5 mM Na4P2O7, 15 mM Triton-X 100). Wound tissue lysates (50 µg) were subjected to Western
immunoblotting and probed for HIF-1α (1:1000, NB100-105, Novus Biologicals, Littleton, CO, USA) α
Tubulin (1:5000, AB40742, Abcam) was used to confirm even protein loading. Commercially available
ELISA kits (Quantikine, RnD Systems, Minneapolis, MN, USA) were used to determine protein levels
of VEGF, CCL2 (MCP-1) and CCL5 (RANTES) in 100 µg of wound tissue lysates, while FGF-2 protein
levels were measured in 50 µg of wound tissue lysates.
4.5. Gene Expression
Total RNA was isolated from wound samples using TRI reagent (Sigma-Aldrich). Furthermore,
300 ng total RNA was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA,
USA) before amplification using the iQ SYBR Supermix (Bio-Rad) in a Bio-Rad Cfx384 thermocycler.
The following mouse primers were used to probe for HIF-1α (F 5′-TCCCTTGCTCTTTGTGGTTGGGT-3′,
R 5′-AACGTAAGCGCTGACCCAGG-3′), VEGF (F 5′-GAGTACCCCGACGAGATAGAGT-3′, R 5′-GGT
GAGGTTTGATCCGCATGA-3′), p65 (F 5′-AGTATCCATAGCTTCCAGAACC-3′, R 5′-ACTGCATTCAA
GTCATAGTCC-3′), CD68 (F 5′-GGGGCTCTTGGGAACTACAC-3′, R 5′-GTACCGTCACAACCTC
CCTG-3′), TGF-β (F 5′-GGATACCAACTATTGCTTCAGCTCC-3′, R 5′-AGGCTCCAAATATAGGGG
CAGGGTC-3′), CD206 (F 5′-CAGGTGTGGGCTCAGGTAGT-3′, R 5′-TGTGGTGAGCTGAAAGGT
GA-3′), CD80 (F 5′-ACCCCCAACATAACTGAGTCT-3′, R 5′-TTCCAACCAAGAGAAGCGAGG-3′),
CD86 (F 5′-CAGCTCACTCAGGCTTATGTTT-3′, R 5′-TGTTTCCGTGGAGACGCAAG-3′), CCL2
(F 5′-GCTGGAGCATCCACGTGTT-3′, R 5′-ATCTTGCTGGTGAATGAGTAGCA-3′), CCL5 (F 5′-GCA
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AGTGCTCCAATCTTGCA-3′, R 5′-CTTCTCTGGGTTGGCACACA-3′) and 36B4 (F 5′-CAACGCAGCA
TTTATAACCC-3′, R 5′-CCCATTGATGATGGAGTGTGG-3′). Relative changes in gene expression were
normalized using the ∆∆Ct method to 36B4 as the housekeeping gene.
4.6. Statistics
All results are expressed as mean ± SEM. All data were compared using an unpaired two-tailed
t-test. Significance was set at a value of p < 0.05.
5. Conclusions
In conclusion, our findings show that broad-spectrum CC-chemokine inhibition via topical
application of 35K enhanced wound closure through the early promotion of neovascularisation.
Furthermore, inhibiting the CC-chemokine class resulted in a reduced inflammatory state as indicated
by reduced NF-κB. Mechanistically, 35K augmented wound angiogenesis via the induction of the
pro-angiogenic cytokine TGF-β, rather than the HIF-1α/VEGF angiogenic pathway. Taken together,
our findings (summarized in Figure 7) demonstrate that broad-spectrum CC-chemokine inhibition
may improve wound healing by suppressing the inflammatory state of the wound while augmenting
wound angiogenesis and suppressing scar formation.
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